LY-3214996

• CAT Number: I007839
• CAS Number: 1951483-29-6
• Molecular Formula: C22H27N7O2S
• Molecular Weight: 453.57
• Purity: ≥95%
• Synonyms: LY-3214996; LY 3214996; LY 3214996.;6,6-dimethyl-2-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-5-(2-morpholinoethyl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one
• Target: Stem Cell/Wnt
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C22H27N7O2S/c1-22(2)19-15(20(30)29(22)9-8-28-10-12-31-13-11-28)14-17(32-19)16-4-6-23-21(25-16)26-18-5-7-24-27(18)3/h4-7,14H,8-13H2,1-3H3,(H,23,25,26)
• InChIKey: JNPRPMBJODOFEC-UHFFFAOYSA-N
• SMILES: CC(N(CCN1CCOCC1)C2=O)(C)C3=C2C=C(S3)C4=CC=NC(NC5=CC=NN5C)=N4

LY-3214996 (Cat No.: I007839) is a potent and selective ERK1/2 inhibitor designed for cancer research. It targets the MAPK/ERK signaling pathway, which is frequently dysregulated in tumors, leading to uncontrolled cell proliferation and survival. By inhibiting ERK1/2, LY-3214996 suppresses tumor growth and enhances the efficacy of combination therapies. It has shown promise in preclinical and clinical studies for treating cancers with RAS/MAPK pathway mutations, including melanoma and colorectal cancer. Its high specificity makes it a valuable tool in oncology drug discovery.

Overview of Clinical Research

Originator: Eli Lilly
Class: Antineoplastics
Mechanism of Action: Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
Orphan Drug Status: No
New Molecular Entity: Yes